Procainamide Challenge: Procedure, Risks, and Results

A procainamide challenge is a supervised drug infusion used to unmask Brugada syndrome, an inherited heart-rhythm disorder that can trigger sudden cardiac arrest in seemingly healthy people. In the largest study to date, covering nearly 950 consecutive patients, the test proved remarkably safe: only two patients (about 0.2%) developed any arrhythmia during the infusion, and both episodes resolved as soon as the drug was stopped. Despite that reassuring safety record, the test raises real questions about accuracy, what a positive or negative result means for your future, and whether newer tools might eventually replace it.

Why the Test Exists

Brugada syndrome is caused by abnormal sodium channels in the heart, mostly in the right ventricle’s outer layer of muscle cells. Under normal resting conditions, many people with the condition have a completely normal-looking ECG. The telltale sign, a distinctive “coved” ST-segment elevation in certain chest leads, can appear and disappear on its own, triggered by fever, heavy meals, sleep, or simply random fluctuation. If a doctor suspects Brugada but the resting ECG is ambiguous, the diagnosis can be stalled indefinitely, an uncomfortable situation for someone who may have survived a cardiac arrest or lost a family member suddenly.

This is where the procainamide challenge fills a gap. Procainamide is a sodium channel blocker: it partially inhibits the same ion channels that are already genetically weakened in Brugada syndrome. By temporarily worsening the existing defect, the drug forces the signature ECG pattern to appear in patients who carry the condition, even when it is hidden at rest. At the cellular level, the sodium channel block exaggerates voltage differences across layers of the right ventricle’s wall, producing the distinctive coved-type ECG pattern that clinicians use to make or rule out the diagnosis.¹

How the Test Is Performed

The test takes place in a hospital or electrophysiology lab with continuous ECG monitoring, intravenous access, and a defibrillator at hand. Procainamide is given as a slow intravenous infusion, typically at a rate of about 10 mg per kilogram of body weight over 20 to 30 minutes. During the infusion, a technician or physician watches the ECG in real time, focusing on the right-precordial leads (the electrode positions most sensitive to Brugada changes).

The infusion is stopped immediately if any of the following occur: the characteristic coved-type ST elevation appears (a positive test), the QRS complex widens beyond a predefined threshold (commonly 130% of its baseline width), significant arrhythmias develop, or the full dose is delivered without any diagnostic change (a negative test). Because procainamide has a plasma half-life that averages about three hours and reaches its distribution equilibrium within roughly 30 minutes of IV administration, the drug’s effects begin to wash out relatively quickly once the drip is turned off.² About half the drug is cleared unchanged through the kidneys, and the main metabolite, N-acetylprocainamide, is also active but has a longer half-life of roughly six hours.³

For this reason, patients with kidney problems need extra caution, because slower clearance can extend the drug’s effects. After the infusion, monitoring continues for a period to confirm the ECG returns toward baseline and no delayed arrhythmias emerge.

Who Gets Tested and How Often the Pattern Appears

The reasons people are referred for a procainamide challenge vary widely, and so does the likelihood that the test will reveal Brugada syndrome. In the large 947-patient study published in Circulation, the yield broke down by clinical scenario:⁴

Unexplained cardiac arrest: about 7% tested positive (type 1 pattern provoked) among 390 survivors.
Family history of Brugada syndrome: roughly 22% tested positive among 135 relatives screened.
Family history of unexplained sudden death: about 7% tested positive among 116 patients.
Baseline suspicious but non-diagnostic ECG: nearly 47% tested positive among 189 patients whose resting ECG already showed a suggestive but ambiguous pattern.
Intermittent spontaneous type 1 pattern: 92% tested positive, effectively confirming the diagnosis in patients whose ECG sometimes showed the full pattern on its own.

An earlier, smaller study of 174 patients reported a similar positive rate of about 7% in the cardiac-arrest and sudden-death groups, and found that five of the twelve patients who tested positive had shown no ST abnormalities at baseline at all. None of the patients with a negative procainamide challenge were later diagnosed with Brugada syndrome during follow-up, which speaks to the test’s negative predictive value.⁵

The practical takeaway is that context drives interpretation. A 7% hit rate in cardiac-arrest survivors sounds low until you consider that ruling out Brugada in the other 93% is just as clinically valuable. For family screening, where the prior probability is higher, the test picks up the condition roughly one time in five.

Safety and What Can Go Wrong

The dominant question for most patients walking into this test is “how dangerous is it?” The short answer, based on the largest available dataset, is that serious complications are rare. In the 947-patient cohort, exactly two patients (0.2%) developed ventricular arrhythmias tied to the procainamide, both of which stopped without intervention when the infusion was discontinued.⁴ No sustained cardiac arrest or death occurred.

That said, the test is not free of side effects. Procainamide predictably slows electrical conduction through the heart, which shows up on the ECG as widening of the PR interval, broadening of the QRS complex, and lengthening of the corrected QT interval. A pediatric study found that every single patient showed some degree of these changes regardless of whether the test was positive or negative: the PR interval lengthened by an average of 14%, the QRS by 13%, and the corrected QT by 15%.⁶ These shifts are expected pharmacological effects, not signs that something has gone wrong. The monitoring team watches them because excessive widening would signal that the drug’s effect is too strong and should be stopped.

Hypotension (a drop in blood pressure) can also occur during the infusion, particularly if the drug is pushed too fast. The controlled infusion rate is partly designed to avoid this. In rare cases, prolonged QT from the drug could theoretically predispose to a different kind of arrhythmia called torsades de pointes, which is why the test is done with a defibrillator nearby and why clinicians track the QT interval in real time.

What a Positive Result Means for Your Future

Getting diagnosed with Brugada syndrome through a drug challenge is not the same, prognostically, as having the pattern show up spontaneously. This distinction matters more than many patients realize. In the 947-patient study, 137 patients who tested positive (with no prior cardiac arrest) were followed for an average of nearly six years. Not one of them experienced the combined arrhythmic endpoint of sudden death or sustained ventricular arrhythmia during that period.⁴

A separate study focused specifically on long-term prognosis found that drug-induced Brugada syndrome carried a better outlook, but only in people who were asymptomatic at the time of diagnosis. For those who had already survived a cardiac arrest or had inducible ventricular arrhythmias during electrophysiology testing, the prognosis was considerably worse: prior cardiac arrest and inducible arrhythmias were independent risk factors for future arrhythmic events.⁷

In practice, this means that a positive procainamide challenge in an asymptomatic person, such as a relative being screened after a family member’s diagnosis, does not automatically lead to an implantable defibrillator. It triggers closer monitoring, lifestyle counseling (avoiding fever-raising situations, certain medications, and excessive alcohol), and potentially genetic testing, but the risk of a lethal arrhythmia remains low enough that aggressive device therapy is usually deferred unless other warning signs emerge.

How Procainamide Compares to Ajmaline

In much of Europe, the go-to drug for this type of challenge is ajmaline, not procainamide. Ajmaline is a more potent and shorter-acting sodium channel blocker, and the choice between the two is partly geographic: ajmaline is not commercially available in the United States and Canada, where procainamide is the standard option. This has created a natural experiment, and researchers have compared the two head to head.

In a study of 425 patients who underwent a sodium channel blocker challenge, positive results occurred far more often with ajmaline (26%) than with procainamide (4%). After adjusting for other variables, ajmaline use was an independent predictor of a positive test, with an odds ratio of about 8.8 compared to procainamide.⁸ Whether this reflects ajmaline’s greater sensitivity (catching more true cases) or a tendency toward false positives (flagging people who do not actually have the condition) is still debated. Researchers have pointed out that a patient could test negative with procainamide and positive with ajmaline, or vice versa, raising real clinical, psychological, and financial consequences depending on where you happen to be tested.

For patients in North America, procainamide is the practical reality, and the large 947-patient dataset suggests it performs well enough: its estimated specificity is very high, and the 92% positivity rate in patients with known intermittent spontaneous patterns implies strong sensitivity in the right context. Still, the disparity with ajmaline is a legitimate limitation worth understanding, especially if you are comparing your result to a family member tested in Europe.

Factors That Can Distort Results

A procainamide challenge does not happen in a vacuum, and several factors can push a borderline case toward a false positive or false negative. Acquired conditions that impair sodium channel function, such as fever, high blood potassium, or the influence of other sodium-channel-blocking medications, can all exaggerate the ECG changes and potentially produce a positive result in someone who would not otherwise meet criteria.⁹ This is why clinicians are supposed to check and correct potassium levels before the test and confirm the patient is not febrile.

Increased vagal tone, which can occur during sleep, after large meals, or in well-trained athletes, also reduces the body’s sodium channel reserve and can tip the ECG toward a Brugada-like appearance. Conversely, sympathetic drive (adrenaline, exercise, anxiety) tends to suppress the pattern, meaning an overly anxious patient during the test might paradoxically mask the finding.

Cocaine and certain other recreational drugs block sodium channels in their own right, and cocaine toxicity can actually mimic or unmask a Brugada-like pattern on the ECG. In cases of cocaine-related arrhythmia, sodium bicarbonate rather than procainamide is used to restore sodium channel function, because giving an additional sodium channel blocker would be dangerous.¹⁰ The broader point is that the test result is a snapshot of the interplay between a patient’s genetic sodium channel reserve and whatever else is acting on those channels at the moment. A single negative result in an unusual physiological state does not permanently exclude the diagnosis.

The Test in Children and Adolescents

Pediatric procainamide challenges deserve separate discussion because children’s hearts respond somewhat differently. In a study of children undergoing the test, the universal ECG changes seen in adults, including prolonged PR, QRS, and QT intervals, appeared in every patient. The corrected QT prolonged to above 460 milliseconds in 76% of the children tested, regardless of whether they had Brugada syndrome.⁶ No sustained arrhythmias or adverse events occurred in that series, which is reassuring for safety.

The QT prolongation finding is worth flagging because it complicates interpretation. If three out of four children show a QT above 460 ms after procainamide regardless of Brugada status, clinicians need to be careful not to overinterpret that specific ECG marker. The diagnostic decision still rests on the characteristic coved-type ST-segment pattern in the right-precordial leads, not on QT prolongation alone. Pediatric testing is less common than adult testing because Brugada syndrome rarely manifests clinically before puberty, but it comes up when a child loses a parent or sibling suddenly and screening is offered to the surviving family.

AI-Assisted Screening and What It Might Replace

One of the more intriguing developments is the use of artificial intelligence to analyze long-duration ECG recordings and potentially catch the spontaneous Brugada pattern that appears and disappears on its own, reducing the need for a drug challenge altogether. In one study, a deep-learning algorithm was applied to 24-hour, 12-lead Holter recordings. The algorithm detected a spontaneous type 1 Brugada pattern in 48% of patients whose diagnosis had been established by procainamide challenge, and in 33% of patients with suspected but unconfirmed Brugada syndrome. It found no Brugada patterns in healthy controls.¹¹

The appeal is obvious: rather than bringing a patient into a supervised setting for an IV drug infusion, you send them home with a wearable monitor and let an algorithm scan thousands of heartbeats for the fleeting pattern. A separate study found that an AI model classified individual ECG tracings from Brugada patients with over 91% accuracy, slightly outperforming experienced clinicians who achieved about 88% on the same set.¹²

These tools are not yet ready to replace the procainamide challenge, however. Brugada syndrome is rare enough that training data remains scarce, which limits how well machine-learning models generalize to new patients.¹³ The most realistic near-term role for AI is as a pre-screening step: patients flagged by an algorithm on an ambulatory recording could be fast-tracked for a drug challenge, while those with no suspicious patterns might be spared the test entirely. Given that the procainamide challenge itself is already quite safe, the real gain from AI screening may be less about avoiding risk and more about reducing the logistical burden and cost of bringing patients into a monitored setting for an infusion that, in most clinical subgroups, will be negative.

The Genetics Connection

A positive procainamide challenge often prompts genetic testing, but the relationship between the two is not as tidy as you might expect. The most studied gene in Brugada syndrome is SCN5A, which encodes the heart’s main sodium channel. Yet in the 174-patient study, genetic testing was done in ten of the twelve patients who tested positive, and only one carried an identifiable SCN5A mutation.⁵ This is consistent with broader estimates in the field: SCN5A mutations are found in only about 20 to 30% of clinically diagnosed Brugada cases, and for the remainder, either other genes or combinations of common genetic variants are responsible, or the genetic basis simply has not been identified yet.

This gap means a negative genetic test does not rule out Brugada syndrome, and a positive procainamide challenge remains the more definitive diagnostic finding. It also means that family screening cannot rely on genetics alone. A relative who tests negative for the family’s known SCN5A variant may still need a procainamide challenge if their clinical picture is suspicious, because they could carry a different genetic contributor that the panel did not cover. The interplay between the drug test and genetic testing is complementary rather than redundant: each catches cases the other misses.